Respiratory multiple test kit

Respiratory Multiple Rapid Test (FluA/FluB/COVID-19/RSV/Adeno/MP) is a lateral flow immunoassay intended for the qualitative detection of nucleocapsid protein antigen from SARS-CoV-2, influenza A virus, influenza B virus, respiratory syncytial virus (RSV) , Adeno virus or Mycoplasma pneumoniae in nasopharyngeal swab or nasal swab specimens. Antigen tests are generally used for acute phase of infection, this test detects the antigen in specimen from individuals who are suspected of relative virus infection within 7 days of symptom onset. This test only provides an aid to diagnosis of novel coronavirus (SARS-CoV-2), influenza A virus, influenza B virus, RSV , Adeno virus and Mycoplasma pneumonia infection. The infection status should be determined in combination with other diagnostic information such as PCR tests or medical image science, exposures and medical history. Positive results only indicate the presence of viral antigens in specimens and cannot determine the infection status. Positive results can be used for patient diversion and rapid management decisions. Negative results cannot rule out the SARS-CoV-2, influenza A virus, influenza B virus, RSV , Adeno virus or Mycoplasma pneumoniae infection, and should not be used as sole basis for treatment or patient management decisions. Both positive and negative results for suspected cases should be determined by a further molecular assay